LALayla A. Abushamat

Layla A. Abushamat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Layla A. Abushamat has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention

    by Yakubu Bene-Alhasan, Vijay Nambi, Layla A. Abushamat, Christie M. Ballantyne

    Lipoprotein(a), or Lp(a), is a genetically determined low-density lipoprotein-like particle that is elevated in approximately one in five individuals worldwide and represents an independent causal risk factor for atherosclerotic cardiovascular disease and calcific aortic stenosis. Elevated Lp(a) levels contribute significantly to residual cardiovascular risk despite optimal management of traditional risk factors. The pathogenicity of Lp(a) derives from its unique structure and enrichment with oxidized phospholipids, conferring proinflammatory, prothrombotic, and proatherogenic properties. Current guidelines recommend at least one-time universal screening, with elevated levels informing personalized decisions regarding lipid-lowering therapy intensification. Novel unapproved therapies, including an antisense oligonucleotide (pelacarsen), small interfering RNAs (olpasiran, lepodisiran), and an oral small molecule (muvalaplin), have demonstrated Lp(a) reductions of up to 99% and are being tested in ongoing phase 3 cardiovascular outcomes trials to determine whether pharmacologic Lp(a) lowering translates into reduced cardiovascular events. We discuss current knowledge on genetics, biology, epidemiology, and measurement of Lp(a), examine its causal association with cardiovascular disease, and discuss emerging therapeutic strategies that may usher in a new era of cardiovascular disease prevention.

  • Open Access

    Finding NEMO (Nuanced Effective Medical Options) for Personalized Cholesterol Management

    by Yakubu Bene-Alhasan, Layla A. Abushamat, Vijay Nambi

  • Eicosapentaenoic acid ethyl ester cardioprotection: beyond triglycerides

    by Tarec K Elajami, Layla A Abushamat, Christie M Ballantyne

    This editorial refers to ‘ Eicosapentaenoic acid ethyl ester, cardiac metabolomic and lipidomic signatures, and cardioprotection in myocardial infarction’,

  • An integrated cardiometabolic genetic testing program in a predominantly Hispanic population within a community setting

    by Bo Yuan, Layla A. Abushamat, Stacey Pereira, Surya Narayan Mulukutla, Grace E. Tietz, Eric Venner, Sara E. Kalla, Breanna Lee, Donna Muzny, Ginger Metcalf, et al.

  • Reducing Cardiovascular Disease Risk in Obesity

    by Layla A. Abushamat, Arsalan Hamid, Vijay Nambi, Huaizhu Wu, Christie M. Ballantyne

  • Open Access

    Proteomic analysis identifies lipoprotein(a)-associated proteins linked to incident atherosclerotic cardiovascular disease events

    by Tiffany R. Bellomo, Seyedmohammad Saadatagah, Jiwoo Lee, Emily E. Bramel, Layla Abushamat, Anika Misra, Tetsushi Nakao, Satoshi Koyama, Aniruddh P. Patel, Sarah Urbut, et al.

    Background: The pathways linking lipoprotein(a) (Lp[a]) to atherosclerotic cardiovascular disease (ASCVD) are unclear. This study aimed to discover Lp(a)-associated plasma proteins and estimate their associations with incident ASCVD. Methods: We analyzed 48,859 UK Biobank participants with measured Lp(a) and proteomic profiles, with replication in 9,416 individuals in the Atherosclerosis Risk in Communities (ARIC) study cohort utilizing a separate proteomic platform. Linear models assessed associations between Lp(a) and protein concentrations adjusted for age, sex, cigarette smoking, diabetes diagnosis, body mass index, systolic blood pressure, hypertension, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, triglycerides, estimated glomerular filtration rate, statin prescription, and the first 10 components of genetic ancestry. Multiple testing correction was performed using the Benjamini-Hochberg FDR method (P < 0.05). We examined how the protein effect sizes from the primary analysis using the outcome of Lp(a) aligned with those for the outcomes of an LPA genetic risk score (GRS) and LDL-C. Cox proportional hazards models quantified hazard ratios (HRs) for protein associations with incident ASCVD. Results: Participants were a mean age of 57 years (SD 8.22), 93.9% European, and 53.8% male, with median follow-up of 8.9 years (IQR 8.3–9.7). Of 1,459 circulating proteins, 164 were significantly associated with Lp(a) after FDR correction, with enrichment for lipid degradation, metabolism, and insulin secretion. In the ARIC study, 10 proteins were replicated with consistent effect estimates. Of these replicated proteins, there were no significant associations observed with an LPA GRS. Only REG4 and VWC2 showed concordant associations with LDL-C (P < 0.001), consistent with their association with Lp(a). Five proteins exhibited concordant associations with Lp(a) and incident ASCVD (ITIH3, DLL1, REG4, VWC2, CBLN4). ITIH3 was positively associated with coronary artery disease (HR 1.13, 95% CI 1.04–1.23), peripheral artery disease (HR 1.42, 95% CI 1.19–1.69), major adverse limb events (HR 1.65, 95% CI 1.14–2.40), carotid stenosis (HR 1.45, 95% CI 1.13–1.85), and ischemic stroke (HR 1.33, 95% CI 1.13–1.55). CBLN4 uniquely showed inverse associations with Lp(a) and disease: higher levels were linked to lower risk of CAD (HR 0.88, 95% CI 0.80–0.96), PAD (HR 0.78, 95% CI 0.64–0.96), and ischemic stroke (HR 0.72, 95% CI 0.60–0.85). Conclusion: Using high-throughput proteomics, we discovered and replicated 10 proteins associated with circulating Lp(a), several of which were independent of genetically-predicted Lp(a). While Lp(a) is highly heritable, these atherogenic proteins represent a non-heritable Lp(a) axis. Clinical Perspective: What’s New?: Ten proteins associated with circulating lipoprotein(a) levels were identified and independently replicated in an external cohort, with associations independent of a genetic risk score. Five proteins (ITIH3, CBLN4, FLL1, REG4, VWC2) were concordantly associated with lipoprotein(a) and incident atherosclerotic cardiovascular disease. Clinical Implications: These proteins may represent pathways through which lipoprotein(a) drives atherosclerosis beyond traditional lipid mechanisms. Future mechanistic studies should investigate the roles of these proteins to guide the development of targeted strategies for preventing atherosclerotic cardiovascular disease.


  • Open Access

    Plain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease

    by Layla A. Abushamat, Pir Ahmad Shah, Robert H. Eckel, Stephen A. Harrison, Diana Barb

  • Open Access

    N-acetylaspartate from fat cells regulates postprandial body temperature

    by Jessica B. Felix, Pradip K. Saha, Evelyn L. de Groot, Lin Tan, Robert Sharp, Elizabeth S. Anaya, Yafang Li, Holly Quang, Nooshin Saidi, Layla Abushamat, et al.

    N-acetylaspartate (NAA), the brain's second most abundant metabolite, provides essential substrates for myelination through its hydrolysis1. However, the physiological roles of NAA in other tissues remain unknown. Here, we show that aspartoacylase (ASPA) expression in white adipose tissue (WAT) governs blood NAA levels for postprandial body temperature regulation. Genetic ablation of Aspa in mice resulted in systemically elevated NAA levels, and the ensuing accumulation in WAT stimulated pyrimidine production. Stable isotope tracing confirmed higher incorporation of glucose-derived carbon into pyrimidine metabolites in Aspa knockout cells. Additionally, serum NAA levels positively correlated with the abundance of the pyrimidine intermediate orotidine 5'-monophosphate, and this relationship predicted lower body mass index in humans. Using whole-body and tissue-specific knockout mouse models, we observed that fat cells provided plasma NAA and suppressed postprandial body temperature elevation. Moreover, unopposed NAA from adipocytes greatly enhanced whole-body glucose disposal exclusively in WAT. Exogenous NAA also increased plasma pyrimidines and lowered body temperature. These data place WAT-derived NAA as an endocrine regulator of postprandial body temperature and define broader roles for metabolic homeostasis.